{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T02:41:01Z","timestamp":1792896061542,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T00:00:00Z","timestamp":1684972800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T00:00:00Z","timestamp":1684972800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Immune reconstitution after hematopoietic stem cell transplantation (HSCT) is a complex and extremely variable process. The<jats:italic>Ikaros<\/jats:italic>transcription factor plays an important role in hematopoiesis in several cell lines, especially in the lymphoid lineage. We hypothesized that<jats:italic>Ikaros<\/jats:italic>might influence immune reconstitution, and consequently, the risk of opportunistic infections, relapse, and graft versus host disease (GVHD). Samples were collected from the graft and from the peripheral blood (PB) of the recipients 3\u00a0weeks after neutrophil recovery. Real-time polymerase chain reaction (RT-PCR) was performed to analyze the absolute and relative<jats:italic>Ikaros<\/jats:italic>expression. Patients were divided into two groups, according to<jats:italic>Ikaros<\/jats:italic>expression in the graft and in the recipients\u2019 PB based on the ROC curves for moderate\/severe cGVHD. A cutoff of 1.48 was used for<jats:italic>Ikaros<\/jats:italic>expression in the graft, and a cutoff of 0.79 was used for<jats:italic>Ikaros<\/jats:italic>expression in the recipients\u2019 PB. Sixty-six patients were included in this study. Median age of patients was 52\u00a0years (range 16\u201380\u00a0years), 55% of them were male, and 58% of them had acute leukemia. Median follow-up period was 18\u00a0months (range 10\u201343\u00a0months). There was no association between<jats:italic>Ikaros<\/jats:italic>expression and the risk of acute GVHD, relapse, or mortality. However, a significant association was observed with the risk of chronic GVHD. Higher<jats:italic>Ikaros<\/jats:italic>expression in the graft was associated with a significantly higher cumulative incidence (CI) of moderate\/severe chronic GVHD according to the National Institute of Health (NIH) classification at two years (54% vs. 15% for patients with lower expression, P\u2009=\u20090.03). A higher<jats:italic>Ikaros<\/jats:italic>expression in the recipients\u2019 PB 3\u00a0weeks after engraftment was also associated with a significantly higher risk of moderate\/severe chronic GVHD (65% vs. 11%, respectively, P\u2009=\u20090.005). In conclusion,<jats:italic>Ikaros<\/jats:italic>expression in the graft and in the recipients\u2019 PB after transplantation was associated with a higher risk of moderate\/severe chronic GVHD.<jats:italic>Ikaros<\/jats:italic>expression should be evaluated in larger prospective trials as a potential biomarker for chronic GVHD.<\/jats:p>","DOI":"10.1038\/s41598-023-35609-3","type":"journal-article","created":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T09:02:16Z","timestamp":1685005336000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Ikaros expression is associated with an increased risk of chronic graft-versus-host disease"],"prefix":"10.1038","volume":"13","author":[{"given":"A. D.","family":"Pereira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V. C.","family":"de Molla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. R. B. M.","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Tucunduva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Novis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. S.","family":"Pires","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. F.","family":"Popi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. A.","family":"Arrais-Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,25]]},"reference":[{"issue":"16","key":"35609_CR1","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1001\/jama.2010.491","volume":"303","author":"A Gratwohl","year":"2010","unstructured":"Gratwohl, A. et al. Hematopoietic stem cell transplantation: A global perspective. JAMA 303(16), 1617\u20131624 (2010).","journal-title":"JAMA"},{"key":"35609_CR2","unstructured":"Phelan, R., Arora, M., & Chen, M. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR US summary slides (2020)."},{"issue":"2","key":"35609_CR3","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.bbmt.2014.10.021","volume":"21","author":"S Arai","year":"2015","unstructured":"Arai, S. et al. Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: A report from the Center for International Blood and Marrow Transplant Research. Biol. Blood Marrow Transp. 21(2), 266\u2013274 (2015).","journal-title":"Biol. Blood Marrow Transp."},{"issue":"1","key":"35609_CR4","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/s41409-020-01017-8","volume":"56","author":"D Wolff","year":"2021","unstructured":"Wolff, D. et al. Post-transplant multimorbidity index and quality of life in patients with chronic graft-versus-host disease-results from a joint evaluation of a prospective German multicenter validation trial and a cohort from the National Institutes of Health. Bone Marrow Transp. 56(1), 243\u2013256 (2021).","journal-title":"Bone Marrow Transp."},{"key":"35609_CR5","unstructured":"Jagasia M.H., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report. Biol. Blood Marrow Transp. 21(3), 389\u2013401.e1 (2015)."},{"key":"35609_CR6","doi-asserted-by":"crossref","unstructured":"Paczesny, S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. The 2014 biomarker working group report. Biol. Blood Marrow Transp. 21(5), 780\u2013792 (2015).","DOI":"10.1016\/j.bbmt.2015.01.003"},{"issue":"7","key":"35609_CR7","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1038\/s41409-018-0092-x","volume":"53","author":"D Wolff","year":"2018","unstructured":"Wolff, D. et al. Biomarkers in chronic graft-versus-host disease: quo vadis?. Bone Marrow Transplant. 53(7), 832\u2013837 (2018).","journal-title":"Bone Marrow Transplant."},{"key":"35609_CR8","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.coi.2017.11.005","volume":"51","author":"B Heizmann","year":"2018","unstructured":"Heizmann, B., Kastner, P. & Chan, S. The Ikaros family in lymphocyte development. Curr. Opin. Immunol. 51, 14\u201323 (2018).","journal-title":"Curr. Opin. Immunol."},{"issue":"1","key":"35609_CR9","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/0092-8674(94)90407-3","volume":"79","author":"K Georgopoulos","year":"1994","unstructured":"Georgopoulos, K. et al. The Ikaros gene is required for the development of all lymphoid lineages. Cell 79(1), 143\u2013156 (1994).","journal-title":"Cell"},{"issue":"2","key":"35609_CR10","doi-asserted-by":"publisher","first-page":"585","DOI":"10.4049\/jimmunol.156.2.585","volume":"156","author":"A Moln\u00e1r","year":"1996","unstructured":"Moln\u00e1r, A. et al. The Ikaros gene encodes a family of lymphocyte-restricted zinc finger DNA binding proteins, highly conserved in human and mouse. J. Immunol. 156(2), 585\u2013592 (1996).","journal-title":"J. Immunol."},{"issue":"3","key":"35609_CR11","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1002\/1521-4141(200203)32:3<720::AID-IMMU720>3.0.CO;2-P","volume":"32","author":"P Kirstetter","year":"2002","unstructured":"Kirstetter, P. et al. Ikaros is critical for B cell differentiation and function. Eur. J. Immunol. 32(3), 720\u2013730 (2002).","journal-title":"Eur. J. Immunol."},{"issue":"2","key":"35609_CR12","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1006\/smim.1998.0113","volume":"10","author":"A Nichogiannopoulou","year":"1998","unstructured":"Nichogiannopoulou, A., Trevisan, M., Friedrich, C. & Georgopoulos, K. Ikaros in hemopoietic lineage determination and homeostasis. Semin. Immunol. 10(2), 119\u2013125 (1998).","journal-title":"Semin. Immunol."},{"issue":"6","key":"35609_CR13","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1182\/blood-2002-05-1336","volume":"101","author":"A Dumortier","year":"2003","unstructured":"Dumortier, A., Kirstetter, P., Kastner, P. & Chan, S. Ikaros regulates neutrophil differentiation. Blood 101(6), 2219\u20132226 (2003).","journal-title":"Blood"},{"issue":"11","key":"35609_CR14","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1056\/NEJMoa1512234","volume":"374","author":"HS Kuehn","year":"2016","unstructured":"Kuehn, H. S. et al. Loss of B cells in patients with heterozygous mutations in IKAROS. N. Engl. J. Med. 374(11), 1032\u20131043 (2016).","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"35609_CR15","doi-asserted-by":"publisher","first-page":"3071","DOI":"10.1172\/JCI98164","volume":"128","author":"D Boutboul","year":"2018","unstructured":"Boutboul, D. et al. Dominant-negative IKZF1 mutations cause a T, B, and myeloid cell combined immunodeficiency. J. Clin. Invest. 128(7), 3071\u20133087 (2018).","journal-title":"J. Clin. Invest."},{"issue":"7","key":"35609_CR16","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1016\/j.bbmt.2015.03.010","volume":"21","author":"MV Gon\u00e7alves","year":"2015","unstructured":"Gon\u00e7alves, M. V. et al. Low counts of plasmacytoid dendritic cells after engraftment are associated with high early mortality after allogeneic stem cell transplantation. Biol. Blood Marrow Transp. 21(7), 1223\u20131229 (2015).","journal-title":"Biol. Blood Marrow Transp."},{"key":"35609_CR17","doi-asserted-by":"crossref","unstructured":"Carneiro T.X., et al. Circulating microparticles as predictive biomarkers of acute graft versus host disease. In: American Society of Hematology Annual Meeting, 2016, San Diego. 58th ASH Annual Meeting Abstracts, v. 128. p. 5778 (2016).","DOI":"10.1182\/blood.V128.22.5778.5778"},{"issue":"6","key":"35609_CR18","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1038\/nprot.2008.73","volume":"3","author":"TD Schmittgen","year":"2008","unstructured":"Schmittgen, T. D. & Livak, K. J. Analyzing real-time PCR data by the comparative C(T) method. Nat. Protoc. 3(6), 1101\u20131108 (2008).","journal-title":"Nat. Protoc."},{"key":"35609_CR19","doi-asserted-by":"crossref","unstructured":"Vandesompele J. et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 3(7), RESEARCH0034 (2002).","DOI":"10.1186\/gb-2002-3-7-research0034"},{"issue":"8","key":"35609_CR20","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror, M. L. et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: A new tool for risk assessment before allogeneic HCT. Blood 106(8), 2912\u20132919 (2005).","journal-title":"Blood"},{"issue":"23","key":"35609_CR21","doi-asserted-by":"publisher","first-page":"3664","DOI":"10.1182\/blood-2014-01-552984","volume":"123","author":"P Armand","year":"2014","unstructured":"Armand, P. et al. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood 123(23), 3664\u20133671 (2014).","journal-title":"Blood"},{"key":"35609_CR22","doi-asserted-by":"crossref","unstructured":"Schoemans H.M. et al. EBMT (European Society for Blood and Marrow Transplantation) Transplant Complications Working Party and the \u201cEBMT\u2212NIH (National Institutes of Health)\u2212CIBMTR (Center for International Blood and Marrow Transplant Research) GvHD Task Force\u201d. EBMT-NIH-CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment. Bone Marrow Transp. 53(11), 1401\u20131415 (2018).","DOI":"10.1038\/s41409-018-0204-7"},{"issue":"5","key":"35609_CR23","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1007\/s12185-015-1785-1","volume":"101","author":"MO Jamil","year":"2015","unstructured":"Jamil, M. O. & Mineishi, S. State-of-the-art acute and chronic GVHD treatment. Int. J. Hematol. 101(5), 452\u2013466 (2015).","journal-title":"Int. J. Hematol."},{"issue":"2","key":"35609_CR24","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.bbmt.2016.09.023","volume":"23","author":"KR Cooke","year":"2017","unstructured":"Cooke, K. R. et al. The biology of chronic graft-versus-host disease: A task force report from the national institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease. Biol. Blood Marrow Transp. 23(2), 211\u2013234 (2017).","journal-title":"Biol. Blood Marrow Transp."},{"issue":"5","key":"35609_CR25","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1080\/1744666X.2018.1463159","volume":"14","author":"HG Ren","year":"2018","unstructured":"Ren, H. G., Adom, D. & Paczesny, S. The search for drug-targetable diagnostic, prognostic and predictive biomarkers in chronic graft-versus-host disease. Expert. Rev. Clin. Immunol. 14(5), 389\u2013404 (2018).","journal-title":"Expert. Rev. Clin. Immunol."},{"issue":"10","key":"35609_CR26","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1016\/j.bbmt.2016.06.020","volume":"22","author":"M Grube","year":"2016","unstructured":"Grube, M. et al. Risk factors and outcome of chronic graft-versus-host disease after allogeneic stem cell transplantation-results from a single-center observational study. Biol. Blood Marrow Transp. 22(10), 1781\u20131791 (2016).","journal-title":"Biol. Blood Marrow Transp."},{"issue":"1","key":"35609_CR27","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.bbmt.2015.10.001","volume":"22","author":"T Teshima","year":"2016","unstructured":"Teshima, T., Reddy, P. & Zeiser, R. Acute graft-versus-host disease: novel biological insights. Biol. Blood Marrow Transp. 22(1), 11\u201316 (2016).","journal-title":"Biol. Blood Marrow Transp."},{"issue":"5","key":"35609_CR28","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1111\/bjh.16190","volume":"187","author":"R Zeiser","year":"2019","unstructured":"Zeiser, R. Advances in understanding the pathogenesis of graft-versus-host disease. Br. J. Haematol. 187(5), 563\u2013572 (2019).","journal-title":"Br. J. Haematol."},{"issue":"16","key":"35609_CR29","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1056\/NEJMoa1203517","volume":"367","author":"C Anasetti","year":"2012","unstructured":"Anasetti, C. et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. N. Engl. J. Med. 367(16), 1487\u20131496 (2012).","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"35609_CR30","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/S1470-2045(09)70225-6","volume":"10","author":"J Finke","year":"2009","unstructured":"Finke, J. et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: A randomised, open-label, multicentre phase 3 trial. Lancet Oncol. 10(9), 855\u2013864 (2009).","journal-title":"Lancet Oncol."},{"issue":"1","key":"35609_CR31","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13045-016-0389-4","volume":"10","author":"MT Rubio","year":"2017","unstructured":"Rubio, M. T. et al. Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine Iv-busulfan myeloablative regimen: A report from the EBMT acute leukemia working party. J. Hematol. Oncol. 10(1), 31 (2017).","journal-title":"J. Hematol. Oncol."},{"issue":"7","key":"35609_CR32","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1182\/blood-2015-09-671834","volume":"127","author":"AS Kanate","year":"2016","unstructured":"Kanate, A. S. et al. Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors. Blood 127(7), 938\u2013947 (2016).","journal-title":"Blood"},{"issue":"9","key":"35609_CR33","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1016\/j.bbmt.2019.05.025","volume":"25","author":"S Ahmed","year":"2019","unstructured":"Ahmed, S. et al. Lower graft-versus-host disease and relapse risk in post-transplant cyclophosphamide-based haploidentical versus matched sibling donor reduced-intensity conditioning transplant for Hodgkin lymphoma. Biol. Blood Marrow Transp. 25(9), 1859\u20131868 (2019).","journal-title":"Biol. Blood Marrow Transp."},{"issue":"49","key":"35609_CR34","doi-asserted-by":"publisher","first-page":"35170","DOI":"10.1074\/jbc.M113.481440","volume":"288","author":"LY Wong","year":"2013","unstructured":"Wong, L. Y., Hatfield, J. K. & Brown, M. A. Ikaros sets the potential for Th17 lineage gene expression through effects on chromatin state in early T cell development. J. Biol. Chem. 288(49), 35170\u201335179 (2013).","journal-title":"J. Biol. Chem."},{"issue":"2","key":"35609_CR35","first-page":"289","volume":"16","author":"KR Schultz","year":"1995","unstructured":"Schultz, K. R., Paquet, J., Bader, S. & HayGlass, K. T. Requirement for B cells in T cell priming to minor histocompatibility antigens and development of graft-versus-host disease. Bone Marrow Transp. 16(2), 289\u2013295 (1995).","journal-title":"Bone Marrow Transp."},{"issue":"3","key":"35609_CR36","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.exphem.2005.12.011","volume":"34","author":"F Patriarca","year":"2006","unstructured":"Patriarca, F. et al. The development of autoantibodies after allogeneic stem cell transplantation is related with chronic graft-vs-host disease and immune recovery. Exp. Hematol. 34(3), 389\u2013396 (2006).","journal-title":"Exp. Hematol."},{"issue":"20","key":"35609_CR37","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1182\/blood-2014-11-613323","volume":"125","author":"H Nakasone","year":"2015","unstructured":"Nakasone, H. et al. Allogeneic HY antibodies detected 3 months after female-to-male HCT predict chronic GVHD and non relapse mortality in humans. Blood 125(20), 3193\u20133201 (2015).","journal-title":"Blood"},{"issue":"12","key":"35609_CR38","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1182\/blood-2012-06-438911","volume":"120","author":"JL Allen","year":"2012","unstructured":"Allen, J. L. et al. B cells from patients with chronic GVHD are activated and primed for survival via BAFF-mediated pathways. Blood 120(12), 2529\u20132536 (2012).","journal-title":"Blood"},{"issue":"13","key":"35609_CR39","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1182\/blood-2013-10-533562","volume":"123","author":"JL Allen","year":"2014","unstructured":"Allen, J. L. et al. Increased BCR responsiveness in B cells from patients with chronic GVHD. Blood 123(13), 2108\u20132115 (2014).","journal-title":"Blood"},{"issue":"20","key":"35609_CR40","doi-asserted-by":"publisher","first-page":"6107","DOI":"10.1158\/1078-0432.CCR-07-1290","volume":"13","author":"S Sarantopoulos","year":"2007","unstructured":"Sarantopoulos, S. et al. High levels of B-cell activating factor in patients with active chronic graft-versus-host disease. Clin. Cancer Res. 13(20), 6107\u20136114 (2007).","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"35609_CR41","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.4049\/jimmunol.1601725","volume":"199","author":"Y Nakayama","year":"2017","unstructured":"Nakayama, Y. et al. Aiolos overexpression in systemic lupus erythematosus B cell subtypes and BAFF-induced memory B cell differentiation are reduced by CC-220 modulation of Cereblon activity. J. Immunol. 199(7), 2388\u20132407 (2017).","journal-title":"J. Immunol."},{"issue":"4","key":"35609_CR42","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1038\/leu.2011.257","volume":"26","author":"Z Kuzmina","year":"2012","unstructured":"Kuzmina, Z. et al. Significantly worse survival of patients with NIH-defined chronic graft-versus-host disease and thrombocytopenia or progressive onset type: Results of a prospective study. Leukemia 26(4), 746\u2013756 (2012).","journal-title":"Leukemia"},{"issue":"8","key":"35609_CR43","doi-asserted-by":"publisher","first-page":"e409","DOI":"10.1016\/S2352-3026(19)30088-2","volume":"6","author":"BM Sandmaier","year":"2019","unstructured":"Sandmaier, B. M. et al. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: A multicentre, randomised, phase 3 trial. Lancet Haematol. 6(8), e409\u2013e418 (2019).","journal-title":"Lancet Haematol."},{"issue":"9","key":"35609_CR44","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/j.bbmt.2017.05.035","volume":"23","author":"A D\u2019Souza","year":"2017","unstructured":"D\u2019Souza, A., Lee, S., Zhu, X. & Pasquini, M. Current use and trends in hematopoietic cell transplantation in the United States. Biol. Blood Marrow Transp. 23(9), 1417\u20131421 (2017).","journal-title":"Biol. Blood Marrow Transp."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-35609-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-35609-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-35609-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T02:41:57Z","timestamp":1729478517000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-35609-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,25]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["35609"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-35609-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,25]]},"assertion":[{"value":"4 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8458"}}